title: Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus.
abstract: OBJECTIVE
  To evaluate the long-term effectiveness of Humalog insulin in lowering post meal glucose excursions.
  
  
  METHODS
  Twenty young subjects with Type 1 diabetes mellitus (DM) who had received insulin-lispro (Humalog) for a least 1 year (mean +/- SD 1.8+/-1.6 years) were studied on two occasions, 3-14 days apart. They consumed a similar breakfast consisting of 450-600 kCal having fasted overnight. The same amount of human soluble Humulin Regular or Humalog insulin was given 10 min before the meal in a randomized, double-blind fashion.
  
  
  RESULTS
  Postprandial glucose excursions at 30, 60, and 120 min were significantly lower (P<0.001, ANCOVA) when subjects received Humalog as compared to human soluble insulin. Serum-free insulin levels were significantly higher (P<0.001, ANOVA) at 30 and 60 min when subjects received Humalog as compared with human soluble insulin. Humalog antibody levels after up to 5.4 years of receiving Humalog insulin were not elevated beyond the values at 1 year.
  
  
  CONCLUSIONS
  We conclude that Humalog insulin is effective in lowering postprandial glucose excursions even after up to 5.4 years of treatment.
authors.affiliation: Barbara Davis Center for Childhood Diabetes, Department of Paediatrics, University of Colorado Health Sciences Center, Denver, USA. Satish.Garg@UCHSC.edu
authors.forename: S K
authors.initials: SK
authors.lastname: Garg
authors.forename: J H
authors.initials: JH
authors.lastname: Anderson
authors.forename: S V
authors.initials: SV
authors.lastname: Perry
authors.forename: T
authors.initials: T
authors.lastname: Mackenzie
authors.forename: P
authors.initials: P
authors.lastname: Keith
authors.forename: M K
authors.initials: MK
authors.lastname: Jennings
authors.forename: M M
authors.initials: MM
authors.lastname: Hansen
authors.forename: H P
authors.initials: HP
authors.lastname: Chase
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D018592:Cross-Over Studies; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D004311:Double-Blind Method; D004435:Eating; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000276:immunology / Q000627:therapeutic use*; D007328:Insulin / Q000031:analogs & derivatives* / Q000276:immunology / Q000627:therapeutic use*; D007330:Insulin Antibodies / Q000097:blood; D061268:Insulin Lispro; D008297:Male; D019518:Postprandial Period; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D007330:Insulin Antibodies; D061268:Insulin Lispro